Genetic Signatures Ltd has released a press release.
510(k) Filing in Preparation for US Commercial Launch
Filed with ASX ·
Watch Genetic Signatures' latest callGenetic Signatures (ASX:GSS) Q4 2026 Earnings Call · Replay · Aug 25Read the transcript of Genetic Signatures (ASX:GSS) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Genetic Signatures Ltd. on 6ix
Earlier from Genetic Signatures
- FDA 510(k) for Gastrointestinal Parasite Kit Submitted
- Influenza B Detection Expected to Impact on Quarter Sales
- Response to ASX Query
- 3base Kit for Antimicrobial Resistance Shows High Detection
- Full Year Statutory Accounts
Later from Genetic Signatures
- Quarterly update and Appendix 4C
- 2023 AGM Chairman's Address and CEO Presentation
- $6.9m R&D tax incentive received
- Capital Raising Presentation
- Genetic Signatures Announces $15.9m Capital Raising
Follow Genetic Signatures into a list and get an email when it puts out news.
Follow Genetic Signatures